Removal of draft wording in the directors report HY accounts

Key points

• Nexalis Therapeutics Ltd identified and corrected draft wording in its half-year report.
• The correction does not change the financial results or other disclosures.
• The company is focused on developing treatments for pain and mental health disorders.
• Nexalis is exploring alternative funding options after the cancellation of a debt facility.

Full summary

Nexalis Therapeutics Ltd has corrected draft wording in the Directors' Report accompanying its half-year financial accounts for the period ending June 30, 2026. The correction pertains to an error in the draft wording on page 2 of the report. The financial results and other disclosures remain unchanged. Nexalis continues to focus on developing treatments for pain and mental health disorders, including Breakthrough Cancer Pain, Panic Disorder, and Treatment-Resistant Depression. The company is also exploring alternative funding options after the cancellation of a debt facility with Linlithgow Family Office.